Brokers Issue Forecasts for Genmab As’ FY2018 Earnings (OTCMKTS:GNMSF)

Genmab As (OTCMKTS:GNMSF) – Equities research analysts at Jefferies Group lowered their FY2018 earnings per share estimates for shares of Genmab As in a research note issued to investors on Friday, according to Zacks Investment Research. Jefferies Group analyst P. Welford now expects that the company will post earnings per share of $4.27 for the year, down from their prior estimate of $4.34.

A number of other analysts have also recently commented on the stock. Zacks Investment Research cut shares of Genmab As from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. JPMorgan Chase & Co. cut shares of Genmab As from an “overweight” rating to a “neutral” rating in a research report on Friday, October 6th.

Genmab As (OTCMKTS GNMSF) remained flat at $$186.75 during trading hours on Monday. The company has a market cap of $11,426.42, a PE ratio of 64.62 and a beta of 0.96. Genmab As has a 1-year low of $163.00 and a 1-year high of $239.75.

COPYRIGHT VIOLATION WARNING: This report was originally published by BBNS and is the property of of BBNS. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://baseballnewssource.com/markets/analysts-issue-forecasts-for-genmab-as-fy2018-earnings-gnmsf/1818331.html.

Genmab As Company Profile

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer in Denmark and internationally. The company markets Arzerra, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia (CCL); and DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM).

Get a free copy of the Zacks research report on Genmab As (GNMSF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Genmab As Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab As and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.